Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Aldeyra reports topline phase III data on reproxalap in dry eye disease

Jan. 8, 2021

REGENXBIO announces development updates for RGX-314 and RGX-202

Jan. 8, 2021

Treatment begins in phase I/IIa trial of AXT-107 in DME

Jan. 7, 2021

Redwood reports further phase II data analysis on RP-101 for dry eye

Dec. 29, 2020

Arctic Vision obtains IND approval for ARVN-001 in China

Dec. 28, 2020

Phase II study of AZR-MD-001 for contact lens discomfort meets primary endpoints

Dec. 22, 2020

Phase III studies of faricimab in DME meet primary endpoint

Dec. 21, 2020

Positive phase II data for PL-9643 in patients with moderate to severe dry eye disease

Dec. 16, 2020

Gene therapy in one eye improves vision in both

Dec. 16, 2020

Phase III KESTREL study of Beovu in DME meets primary endpoint

Dec. 15, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...